Member news

BRAIN AG publishes its Annual Report for the Financial Year 2019/20

More at brain-biotech.com…

Medigene expands patent protection of its technologies in key markets, the USA and Europe

More at medigene.com…

CTI Clinical Trial & Consulting Recognized as a Top Enrolling Site in Janssen’s ENSEMBLE Phase 3 COVID-19 Vaccine Trial

More at mailchi.mp…

AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative

More at aicuris.com…

Roquette and BRAIN Group agree on production scale-up for protein sweetener

More at brain-biotech.com…

MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

More at morphosys.com…

PAION announces exclusive licensing agreement with La Jolla Pharmaceutical for GIAPREZA(TM) (ANGIOTENSIN II) and XERAVA(TM) (ERAVACYCLINE) in Europe

More at paion.com…

InflaRx Provides Update on Vilobelimab (IFX-1) Development

More at inflarx.de…

CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

More at curevac.com…

Scale-Up Concept at PAN-Biotech from the Regensburg Bioregion

More at biopark-regensburg.de…

MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference

More at morphosys.com…

AiCuris to Present at the 39th Annual J.P. Morgan Healthcare Conference

More at aicuris.com…

CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy

More at cevec.com…

Evotec to attend upcoming investor conferences

More at evotec.com…

InflaRx to Present at Upcoming Annual J.P. Morgan Healthcare Conference

More at inflarx.de…

PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM (BYFAVO) IN GENERAL ANESTHESIA IN SOUTH KOREA

More at paion.com…

CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV - joint press release

More at curevac.com…

MorphoSys Appoints Sung Lee as Chief Financial Officer

More at morphosys.com…

InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis

More at inflarx.de…

Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin

More at atriva-therapeutics.com…

MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab

More at morphosys.com…

Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb

More at evotec.com…

Adrenomed Supervisory Board appoints Dr. Wolfgang Baiker as CEO

More at adrenomed.com…

European innovation reaches EU population: MIG Fonds` portfolio company BioNTech achieves positive CHMP opinion for the first COVID-19 and mRNA vaccine

More at mig.ag…

Participation at upcoming virtual conferences

More at medigene.com…

Evotec partners with Alloy Therapeutics to expand its antibody discovery platform

More at evotec.com…

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

More at evotec.com…

Human SARS-CoV-2 neutralizing antibody COR-101 demonstrates high efficacy in a COVID-19 animal model and is ready to be used in clinical studies to treat COVID-19 patients

More at corat-therapeutics.com…

Evotec achieves key milestones in its collaboration with Bristol Myers Squibb on targeted protein degradation

More at evotec.com…